{'fraction_non_alphanumeric': 0.02459016393442623, 'fraction_numerical': 0.01639344262295082, 'mean_word_length': 5.601351351351352, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Genetic imbalance related to cisplatin-based chemoresistance in epithelial ovarian cancer.

PURPOSE OF INVESTIGATION
To identify genetic imbalance related to chemoresistance in epithelial ovarian cancer.


METHODS
We screened abnormal chromosomal regions in cisplatin-resistant and cisplatin-sensitive human ovarian cancer cell lines employing comparative genomic hybridization (CGH). We also documented non-random chromosome gains and losses with cisplatin-resistant and cisplatin-sensitive primary epithelial ovarian tumors from patients.


RESULTS
There were extensive chromosome changes in cisplatin-resistant and cisplatin-sensitive cell lines. Gains of 1q12-22, 17q21-22 and loss of 3p21-24 were significantly more common in drug-resistant tumors from patients compared to the drug-sensitive group.


CONCLUSIONS
The special chromosomal aberrances might provide us with a clue for further investigation of the dominant mechanism that leads to a drug-resistant phenotype.